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We studied whether nephrotoxic drug administration
sensitizes to acute renal failure (ARF) by administering
a sub-nephrotoxic dose of gentamicin. This pre-treatment
sensitized animals with no sign of renal injury to develop ARF
when exposed to a second potential nephrotoxic drug, also
given at sub-nephrotoxic doses that would be otherwise
harmless to non-sensitized animals. We identified urinary
ganglioside M2 activator protein (GM2AP) as a biomarker
of an enhanced sensitivity to suffer ARF following sub-
nephrotoxic treatment with gentamicin. Sub-nephrotoxic
gentamicin did not alter renal GM2AP gene expression or
protein levels, determined by reverse transcriptase-PCR,
western blot, and immunostaining, nor was its serum level
modified. The origin of increased GM2AP in the urine is
thought to be a defective tubular handling of this protein
as a consequence of gentamicin action. Hence, markers
of acquired sensitivity may improve the prevention of ARF
by enhancing our capacity to monitor for this condition,
in a preemptive manner.
Kidney International (2010) 78, 1006–1015; doi:10.1038/ki.2010.267;
published online 18 August 2010
KEYWORDS: gentamicin; GM2AP; nephrotoxicity; sensitization to acute
kidney injury; urinary markers
Acute renal failure (ARF) is an extremely serious condition in
which the renal excretory function abruptly falls within a few
hours or days after an insult to the kidneys.1,2 ARF still leads
to death in 50% of the cases, a number that grows to 80% if
multiorgan damage occurs.3–6 The most common causes of
ARF are renal ischemia, obstruction of the urinary ways, and
drug nephrotoxicity.7 A key determinant for a successful
clinical handling of ARF is an early diagnosis, which
significantly improves therapeutic intervention and out-
come.8,9 Traditionally, ARF has been diagnosed through
measurable symptoms of renal dysfunction, such as the
increase in serum creatinine and blood urea nitrogen (BUN)
concentrations, or changes in the fractional excretion of
sodium.9 However, owing to compensatory adaptation, renal
dysfunction only appears after an extensive loss of functional
nephrons occurs.10 Consequently, a new generation of
biomarkers (mostly urine biomarkers) is under development,
associated with early pathophysiological events underlying
the incipient acute kidney injury (AKI), before it turns into
an overt ARF. They, most significantly, include kidney injury
molecule 1 (KIM-1), neutrophil gelatinase-associated lipoca-
lin, and others.9
Gentamicin is an aminoglycoside antibiotic widely used
against Gram-negative infections. The most important side
effect of this drug is its nephrotoxicity,11,12 which occurs in
B10–25% of therapeutic courses, despite correct dosage and
hydration status monitoring.13–15 Gentamicin nephrotoxicity
may range from a mere transient renal dysfunction to a
severe ARF. Gentamicin produces tubular lesions, affecting
mostly the proximal segment, with no gross modification of
glomerular structures. Tubular lesions vary from a mild
sloughing of the brush border to a generalized tubular
necrosis.11,16,17 Besides, gentamicin has been shown to exert
functional glomerular12,18–22 and vascular effects23–25 that,
depending on the dose, contribute to a larger or lesser extent
of renal dysfunction.26
However, it is not yet well characterized to what extent a
subtoxic treatment with gentamicin sensitizes individuals to
ARF, such as the ARF induced by subsequent sub-nephrotoxic
or ig ina l a r t i c l e http://www.kidney-international.org
& 2010 International Society of Nephrology
Received 4 January 2010; revised 9 June 2010; accepted 24 June 2010;
published online 18 August 2010
Correspondence: Francisco J. Lo´pez-Herna´ndez, Unidad de Investigacio´n,
Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, 37007
Salamanca, Spain. E-mail: flopezher@usal.es
4These authors share first authorship.
5These authors share senior authorship.
1006 Kidney International (2010) 78, 1006–1015
exposure to another potentially nephrotoxic agent. A typical
clinical situation exists, where a patient treated with
gentamicin showing no signs of renal disease is thereupon
given another potentially nephrotoxic agent, such as another
drug, or a diagnostic contrast medium, also within a
theoretically subtoxic regime. These scenarios pose relevant
clinical situations of special importance for its hidden nature,
which should be addressed from the diagnostic and
therapeutic perspectives. In this study, we demonstrate that
a sub-nephrotoxic regime of gentamicin primes the rats to
develop an ARF induced by a subsequent or concomitant
exposure to sub-nephrotoxic doses of a second nephrotox-
icant. We also show that the urinary level of ganglioside M2
activator protein (GM2AP) may be used to identify this
condition. Urinary levels of GM2AP could also serve for the
early diagnosis of gentamicin-induced ARF. Detection of the
increased risk enables a preemptive handling of drug toxicity
by anticipating situations that can result in injury, before the
slightest alterations that are usually observed arise.
RESULTS
Characterization of a sub-nephrotoxic regime of gentamicin
A sub-nephrotoxic regime of gentamicin was identified to test
whether it would induce sensitisation to ARF in the absence of
a direct deleterious effect on the kidneys. After pilot studies, a
regime of six daily consecutive doses of 50 mg/kg/day
gentamicin (G-50 group) was observed to exert no obvious
renal injury symptoms. It was further characterized to ensure
the absence of nephrotoxicity. Survival during the whole
treatment was identical to that of control rats (100%), whereas
in rats treated with a nephrotoxic regime of gentamicin
(150 mg/kg/day; G-150 group), which developed a clear ARF,
survival decreased to 50%. Similarly, body weight increased by
a 3–4% in control and G-50 animals, whereas it was reduced by
4–5% in G-150 rats. As shown in Figure 1, we were unable to
find a single marker of renal damage or dysfunction in G-50
rats, when compared with controls. On the contrary, G-150 rats
underwent a typical and overt ARF characterized by an increase
in plasma creatinine concentration (Crpl) and BUN, proteinur-
ia, increased fractional excretion of sodium, and the presence of
urinary (i.e., increased N-acetyl-glucosaminidase (NAG) excre-
tion) and renal tissue (KIM-1, plasminogen activator inhibitor
1, and vimentin) markers of tubular lesion (Figure 1a–f). A
gross morphological examination of renal slices showed that
renal parenchyma in G-50 was indistinguishable from that of
control rats, whereas a clear tubular necrosis and obstruction
was evident in G-150 rats (Figure 1g). These results indicate
that the G-50 regime exerts no apparent deleterious action on
the kidneys, as evaluated by the finest diagnostic methods
available.
Sub-nephrotoxic gentamicin sensitizes to ARF
Under these sub-nephrotoxic circumstances, we tested
whether the G-50 regime sensitizes rats to ARF, e.g., by
reducing the nephrotoxicity threshold of another potential
nephrotoxicant. We first used uranyl nitrate (UN), which we
titrated for dose-nephrotoxic effect in pilot studies. A single
dose of 0.5 mg/kg UN was found to lack nephrotoxic effects,
which was confirmed in further experiments (Figure 2).
However, when this dose of UN was administered to rats
previously treated with G-50, a clear ARF ensued, which was
not observed in control rats or in that treated with UN or
G-50 alone. This ARF was characterized (Figure 2a–d) by an
increase in Crpl, BUN and NAG excretion, proteinuria, and a
decrease in creatinine clearance. This sensitization appears
along with the first sub-nephrotoxic dose of gentamicin and
lasts at least 1 week after gentamicin withdrawal. This is
evidenced by the increase in serum creatinine in rats that were
given the single dose of UN at the onset of the gentamicin
regime, as well as in rats in which UN is administered 1 week
after cessation of the gentamicin treatment (data not shown).
Interestingly, the sensitization produced by gentamicin is also
effective on other potentially nephrotoxic drugs, such as the
antineoplastic cisplatin or the iodinated contrast medium
iohexol. Figure 2e–f shows how rats, previously exposed to
G-50 for 6 days, suffered a renal damage when subsequently
exposed to iohexol (in 24 h) and cisplatin (in 2 days), both used
at sub-nephrotoxic doses (titrated in previous pilot studies).
This is evidenced by increased serum creatinine and BUN, and
elevated NAG excretion.
GM2AP is identified in the urine as a marker of sensitized
animals
Next, we performed a differential proteomic analysis compar-
ing the urine of control rats and G-50 rats at the end of the
treatment, before the administration of the second nephro-
toxicant. The objective of this study was to identify whether
proteins increased or decreased in the urine of G-50 (sensitized
to AKI) compared with control (non-sensitized to AKI) rats,
which might prospectively serve as biomarkers of gentamicin-
induced sensitization to AKI. As shown in Figure 3a, both
urinary proteomes were almost identical. However, a protein
was clearly increased in the urinary proteome of G-50,
which was unambiguously identified using liquid chromato-
graphy electrospray ionization quadrupole time-of-flight
mass spectrometry and matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry as GM2AP. A
polyclonal antibody raised in rabbits against an epitope
found in rat and human GM2AP further confirmed the
increased levels of GM2AP in the urine of G-50 using western
blot analysis (Figure 3b). Furthermore, the urine of eight
patients treated with gentamicin for at least 2 days was
analyzed using western blot for the level of GM2AP, and
compared with that of eight sex and age matching untreated
individuals. A total of seven of eight gentamicin-treated
patients, whereas only two of eight untreated controls,
showed increased levels of GM2AP in the urine, also
determined using western blot analysis (Figure 3c).
Early diagnosis capacity of GM2AP in gentamicin-induced AKI
We also decided to study the early diagnostic capacity of
urinary GM2AP on an animal model of gentamicin-induced
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ARF. A time course experiment revealed that, in this model,
GM2AP appears in the urine from the first day of treatment
with overtly nephrotoxic doses of gentamicin, largely
preceding not only classical markers such as serum
creatinine, BUN, NAG excretion, or proteinuria, but also
the new, earlier, and more sensitive urinary markers of AKI,
KIM-1, and plasminogen activator inhibitor 1 (Figure 4a).
Furthermore, the level of GM2AP in the urine progressively
increased with time, which makes it potentially suitable for
monitoring AKI evolution induced by gentamicin in a much
more specific manner than other novel markers. GM2AP also
appears in the urine of overtly nephrotoxic rats as a
consequence of cisplatin or UN administration at toxic doses
(Figure 4b). In the case of cisplatin, GM2AP appears in the
urine in parallel or after KIM-1 (Figure 4c). These results
indicate that urinary GM2AP, in the absence of damage
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Figure 1 |Absence of renal effects after sub-nephrotoxic gentamicin. (a) Plasma creatinine concentration, (b) blood urea nitrogen
concentration (BUN), (c) proteinuria, (d) fractional excretion of sodium (FE-Na), and (e) N-acetyl-glucosaminidase (NAG) excretion after 6
days of treatment with saline (C), 50 mg/kg/day gentamicin (G-50), or 150 mg/kg/day gentamicin (G-150); n412. (f) Representative images
of western blot analysis of plasminogen activator inhibitor 1 (PAI-1), kidney injury molecule 1 (KIM-1), and vimentin levels in renal tissue
homogenates from three randomly selected animals from C, G-50, and G-150 groups. (g) Representative images (400 ) of the cortex and
medulla of hematoxilin–eosin-stained renal sections from C, G-50, and G-150 rats (n¼ 6). K, Po0.05 with respect to C; , Po0.05 with
respect to G-50.
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markers, likely reflects the increased risk of ARF induced by
gentamicin, because further exposure to the drug produces
an overt ARF.
Urinary GM2AP results from an altered renal handling
of the filtered blood-borne protein
To unravel the origin of the urinary GM2AP, we studied the
effect of gentamicin on the presence and production of
GM2AP in renal tissue, the urine, and the blood. The
immunohistochemical analysis of GM2AP distribution in
renal tissue shows (Figure 5a and b) that this protein is
mainly located in the renal cortex, with great selectivity,
within the proximal tubules. The latter is evidenced by a
perfect co-staining of GM2AP with the proximal tubule-
restricted protein megalin, and the absence of co-staining
with the distal tubule-borne protein calbindin. Sub-nephro-
toxic gentamicin (G-50) did not modify the histological
distribution or apparent expression level of GM2AP (Figure
5a and b). Western blot analysis of total GM2AP protein level
in renal tissue homogenates (Figure 5c), as well as GM2AP
gene expression (by reverse transcriptase-PCR; Figure 5d),
confirmed the lack of effect of gentamicin on the renal
expression of the protein. GM2AP was detected in the
serum and its serum levels were not altered by G-50.
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Figure 2 | Sub-nephrotoxic gentamicin sensitizes to acute renal failure. (a) Time-course evolution of plasma creatinine and BUN
concentration, (b) proteinuria, (c) urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) levels,
(d) N-acetyl-glucosaminidase (NAG) excretion, and creatinine clearance of rats treated as indicated in the upper, left panel of a; n¼ 6.
K, Po0.05 with respect to C; J, Po0.05 with respect to uranyl nitrate (UN); and ’, Po0.05 with respect to G. (e) Plasma creatinine
and BUN concentration and (f) NAG excretion of rats treated as indicated in the left panel, in which uranyl nitrate was substituted by iohexol
or cisplatin; n¼ 4; K, Po0.05 with respect to iohexol or cisplatin.
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However, G-150 treatment significantly increased serum
GM2AP (Figure 5e).
In acute experiments with anesthetized rats, a bolus
administration of a high dose of gentamicin induced a rapid
increase in the urinary excretion of GM2AP (Figure 5g). The
increased excretion declined after 3 h, probably correlating
with the bioavailability of gentamicin. Interestingly, when,
under similar circumstances, kidneys were perfused in situ
with Krebs solution (instead of blood) by means of an
extracorporeal circuit, gentamicin did not produce an
increase in urinary GM2AP (Figure 5h). All together, these
results indicate that the increase in urinary GM2AP produced
by gentamicin is an acute effect which is tightly dependent on
the presence of gentamicin and, most importantly, that the
urinary GM2AP comes from the blood and not from renal
tissues. These results can be explained by an altered renal
handling of GM2AP (e.g., reduced reuptake) as the mechan-
ism responsible for its increase in the urine. In fact, GM2AP
appears in the urine shortly after treatment with maleate
(Figure 5f), indicating that it is transported by the megalin
complex (see discussion). This is further supported by the
colocalization of GM2AP and megalin in proximal tubule
cells within subcellular structures, probably being endocytosis
vesicles, as revealed by confocal microscopy (Figure 5b; lower
panel).
DISCUSSION
Our experiments show that gentamicin-induced sensitization
to ARF, a condition hitherto largely underestimated, is
distinctly differentiated from early and mild renal injury. It
has a potentially high clinical relevance because it poses an
unnoticed risk of ARF. The recognition of acquired
sensitization to ARF as an existing and relevant pathological
state makes obvious the necessity to identify tools to create a
level of diagnosis for its detection and appropriate clinical
handling. Our results also show that the increased urinary
level of GM2AP is associated with the sensitization to AKI
induced by sub-nephrotoxic gentamicin. They further show
that an increased level of GM2AP also appears in the urine of
rats undergoing an overt ARF and, in the case of gentamicin-
induced AKI, urinary GM2AP appears earlier than other
sensitive markers such as KIM-1 or plasminogen activator
inhibitor 1. However, in the case of other nephrotoxicants,
such as cisplatin, urinary GM2AP is elevated in parallel or
even after the appearance early damage marker KIM-1. This
fact has special importance because GM2AP might be
exploited also for an etiological and selective diagnosis of
AKI within the very early stages of the disease. The sub-
nephrotoxic and the early nephrotoxic situations related to
gentamicin treatments show the common characteristic of
lacking the markers of tissue damage, while showing
increased urinary levels of GM2AP. As such, monitoring
the progressive increment of the urinary level of GM2AP
from the onset of a gentamicin regime will provide means of
detecting the increasing risk of an AKI burst as a consequence
of further gentamicin administration or treatment with
another potential nephrotoxicant.
In the case of the sensitization to AKI, GM2AP urinary
excretion would serve as a diagnostic tool to discern which
patients have acquired an increased risk as a consequence of a
gentamicin regime, when contemplating the need of subject-
ing them to additional potentially nephrotoxic circumstances
like the administration of other drugs. A typical and relevant
case, from the clinical and socioeconomic point of views, is
posed by the fact that 0.6–2.3% of not-at-risk patients
undergoing a contrast radiography, with no previous history
of renal disease, develop some degree of AKI.27 We propose
that a part of this patient group might be silently coursing
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Figure 3 | Increased urinary level of ganglioside M2
activator protein (GM2AP) in gentamicin-sensitized rats and
gentamicin-treated humans. (a) Representative bidimensional
electrophoresis (2D) gels of urine from rats treated with saline
(control) or 50 mg/kg/day gentamicin (G-50) during 6 days (n¼ 4).
(b) Representative images of western blot analysis of GM2AP
and neutrophil gelatinase-associated lipocalin (NGAL) in the urine
of four randomly selected rats from control and G-50 groups,
and an acute kidney injury-positive control (urine from a rat
treated with 150 mg/kg/day gentamicin, otherwise as in G-50).
(c) Representative images of western blot analysis of GM2AP,
NGAL, and kidney injury molecule 1 (KIM-1) in the urine of eight
patients treated with gentamicin and eight sex- and age-matched
untreated individuals. Their gender, age, weight, plasma
creatinine concentration (Crpl), blood urea concentration, and
glomerular filtration rate estimated by the Modification of Diet in
Renal Disease (MDRD) study equation or the Cockroft–Gault (C–G)
equation are provided (when known).
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with an increased risk to AKI owing to a previous treatment
or exposure to an environmental agent that has induced no
clinical symptoms of renal lesions, such as a treatment with
gentamicin. The urinary level of GM2AP could be used as a
marker to detect this risk. Very interestingly, urinary GM2AP
is found to be increased (to a variable degree) in most
patients treated with gentamicin for at least 3 days, and
whose estimated glomerular filtration rate and urinary levels
of sensitive renal damage markers (e.g., neutrophil gelatinase-
associated lipocalin, KIM-1) remain normal during analysis.
Identification of markers of risk should be extended over
other nephrotoxic drugs and insults, including renal ischemia
and obstruction of the urinary ways.
GM2AP is an 18–24 kDa substrate cofactor for the
lysosomal b-hexosaminidase A implicated in GM2 ganglio-
side metabolism.28 It has also been proposed as an intra and
intercellular glycosphingolipid transporter.29–31 GM2AP is
mainly driven to the lysosomes through typical trans-Golgi
mannose-6-phosphate receptor-dependent32 and -indepen-
dent33 pathways. About one third of the synthesized protein
is secreted.32 Because, even at low doses, gentamicin
accumulates in the lysosomes, endosomes, and Golgi;34–37
modulates lipid metabolism, signalling, and function;14,38–41
and interferes with endosomal traffic,42,43 it was tempting to
think that the mechanism of gentamicin-induced increase in
urinary GM2AP has to do with alterations in the cellular
handling of this protein resulting in its higher secretion,
production, or both. Our experiments indicate that, as a
result of gentamicin treatment, the renal expression of
GM2AP is not modified, and that the origin of the increased
urinary level of GM2AP is not the renal tissue, but a blood
origin. Owing to its low molecular weight, GM2AP is
expected to cross the glomerular filtration barrier freely.44–46
Our data point at an alteration in its tubular handling as the
cause of its urinary appearance.
In the case of the sub-nephrotoxic regime of gentamicin
(G-50), the increased urinary level of GM2AP is a highly
specific event, being one of the very few proteins showing
higher excretion than in control animals. Contrarily, in the
urine of animals treated with nephrotoxic regimes of
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Figure 4 |Ganglioside M2 activator protein (GM2AP) in the urine of nephrotoxic rats. (a) Time-course evolution of plasma creatinine
concentration (Crpl), creatinine clearance, urinary excretion of N-acetyl-glucosaminidase (NAG), proteinuria (n¼ 6), and representative (n¼ 3)
images of western blot of urinary kidney injury molecule 1 (KIM-1), plasminogen activator inhibitor 1 (PAI-1), and GM2AP excretion of
rats treated during 6 days with 150 mg/kg/day gentamicin. (b) Crpl and representative images of western blot analysis of urinary GM2AP
of rats treated with saline (control) or a nephrotoxic dose of uranyl nitrate (5 mg/kg) or cisplatin (10 mg/kg). (c) Time-course evolution
of Crpl (n¼ 4) and representative images of western blot analysis of urinary GM2AP and KIM-1 of rats treated with saline (control) or cisplatin
(10 mg/kg).
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gentamicin, cisplatin, and UN, the increased GM2AP urinary
levels might be the result of a less specific and defective renal
handling of proteins leading to an overt and unselective
proteinuria. Gentamicin is transported into the proximal
tubule epithelial cells by the apical protein–endocytic
transport complex megalin/cubilin.47 The complex megalin/
cubilin has been shown to mediate the reabsorption of a wide
variety of proteins.48 Gentamicin competes with filtered
proteins for this transporter and augments their urinary
excretion,21,49–52 even in an acute manner.51
As such, it is reasonable to hypothesize that a plausible
origin of the increased urinary excretion of GM2AP in sub-
nephrotoxic circumstances is a submaximal competition of
gentamicin for the GM2AP tubular transporter (likely the
megalin/cubilin complex). Indeed, our results suggest that
GM2AP is reabsorbed in the proximal tubule by the megalin
complex. First, megalin and GM2AP colocalize in spotty
subcellular structures in proximal tubule cells, which are
likely the endosomal vesicles. Second, acute treatment with
maleate produces a rapid appearance of GM2AP in the urine.
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Figure 5 |An altered tubular handling of ganglioside M2 activator protein (GM2AP) causes its increase in the urine. (a) Representative
images (n¼ 3) of renal tissue sections from rats treated with saline (C) or 50 mg/kg/day gentamicin (G-50) during 6 days, stained with
anti-GM2AP. Upper panels (100 ) show the cortex and medulla. Lower panels (400 ) show an amplified area of the renal cortex. (b) In the
upper panels, representative (n¼ 3) immunofluorescence co-staining images of GM2AP and calbindin (left), and GM2AP and megalin (right).
In the lower panels, detailed confocal microscopy image of megalin and GM2AP co-staining. Red represents GM2AP, green represents
calbindin or megalin, and orange shows co-staining. (c) Western blot analysis of GM2AP and extracellular signal-regulated kinase 1
(Erk-1) level in three randomly selected renal tissue homogenates from rats treated with saline (C), 50 mg/kg/day gentamicin (G-50),
or 150 mg/kg/day gentamicin (G-150) during 6 days. (d) Reverse transcriptase-PCR (RT-PCR) amplification of the renal mRNA of GM2AP
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from four randomly selected C, G-50, and G-150 rats. (e) Representative images
of western blot analysis of GM2AP and angiotensinogen (ANGTNG) level in two randomly selected serum samples from C, G-50, and
G-150 rats. (f) Representative images (n¼ 5) of western blot analysis of the time-course level of GM2AP in the urine of rats treated
intravenously with a bolus of sodium maleate (400 mg/kg). (g) Representative images (n¼ 4) of western blot analysis of the time-course
level of GM2AP in the urine of rats treated intravenously with a bolus of saline (Cþ ) or 100 mg/kg gentamicin (Genta). (h) Representative
images (n¼ 4) of western blot analysis of the time-course level of GM2AP in the urine of rats with their left kidney perfused with isosmotic
solution (Cþ ) or isosmotic solution containing 1.5 mg/ml gentamicin during 5 h. B, basal.
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Maleate treatment has been shown to induce the shedding of
megalin into the urine and to impair megalin-mediated
reabsorption.53 In fact, both maleate54 and gentamicin55,56
have been used experimentally to inhibit megalin-dependent
endocytosis. It is further hypothesized that under mild
competition circumstances, only a few proteins showing the
least affinity for the system would be displaced, GM2AP
being one of the first. This is supported by the uneven effect
of gentamicin on the increased excretion of different
proteins, the excretion of ones being increased by orders of
magnitude that of others.51 Increasing competition (i.e., by
higher gentamicin concentrations) would bring about the
displacement of more proteins that, together with a
dysfunctional necrotic tubular epithelium, would produce a
full range proteinuria like that seen during overtly nephro-
toxic circumstances with gentamicin and other drugs.
In conclusion, our study opens new possibilities for the
improvement of AKI diagnosis by providing a potential
marker of the enhanced risk of AKI induced by gentamicin, a
condition that has hitherto been mostly uncharacterized,
quite underestimated, and impossible to diagnose, but which
might have a high clinical and socioeconomic repercussion.
The capacity to detect and prospectively quantify AKI risk
through the determination of biochemical parameters may
help to overturn drug-induced sensitization to AKI. How-
ever, the most important result of this work is the realization,
through this proof-of-concept, of new possibilities for a more
rational and personalized utilization of drugs in the clinical
practice, by anticipating the increased susceptibility and risk
of damage, injury, or alteration posed by drugs even in the
absence of detectable signs of toxicity.
METHODS
Reagents
Unless otherwise indicated, products were purchased from Sigma.
Gentamicin sulphate was kindly provided by Schering-Plough. For
the preparation of an anti-GM2AP serum, female New Zealand
White rabbits were injected with a synthetic immunogen corre-
sponding to the rat and human GM2AP partial peptide sequence
SWDNCDEGKDPAVI. After three immunizations, the serum was
purified through a HiTrap TM Protein G HP column (GE
Healthcare Bio-Sciences AB, Madrid, Spain) and kept at 20 1C
for further use.
Animal models and experimental protocols
In-house bred, female Wistar rats weighing 190–230 g were divided
into the following experimental groups: (i) control: rats treated
intraperitoneally during 7–13 days with saline (0.9% NaCl), once
daily, (ii) G-50: rats treated with 50 mg/kg/day gentamicin during 6
days, (iii) G-50-NU: rats treated with 50 mg/kg/day gentamicin
during 6 days and on the seventh day, treated with a single intra-
peritoneal dose of 0.5 mg/kg UN or cisplatin (10 mg/kg) or iohexol
(2.1 g I/kg, GE Healthcare), (iv) NU: rats treated intraperitoneally
with saline (0.9% NaCl) once daily during 6 days and on the seventh
day, treated with a single intraperitoneal dose of 0.5 mg/kg UN or
cisplatin (10 mg/kg) or iohexol (2.1 gI/kg), and (v) G-150: rats treated
with 150 mg/kg/day gentamicin during 6 days. Rats were individually
allocated in metabolic cages under controlled conditions. Urine and
plasma were obtained and stored at 80 1C. Only for western blot
studies, some plasma was depleted of albumin through Murine
Albumin Depletion Columns (Qiagen, Madrid, Spain) at the
moment of use. At the end of treatments, kidneys were perfused
with heparinized saline and immediately dissected. Half of the
kidney was fixed in paraformaldehyde for histological studies. The
remaining renal mass was frozen at 80 1C for ulterior western blot
and gene expression studies.
Characterization of renal function
Plasma and urine creatinine, (Crp and Cru, respectively) and BUN
concentrations were determined using an automated analyzer
(Reflotron, Roche Diagnostics, Barcelona, Spain). This method has
a lower detection limit of 0.5 mg/dl for creatinine. Creatinine
clearance (ClCr)¼Cru 24-hour urine outputCrp1. Urine
protein concentration was measured by the Bradford method,57
and urine NAG activity by a commercial enzymatic test (Roche
Diagnostics). Sodium (Na) concentration was measured by indirect
potentiometry in a Modular Analytics System (Roche Diagnostics).
Fractional excretion of sodium (FE-Na) was calculated as
(100 urinary NaCrp)/(plasma NaCru).
Histological studies
Paraformaldehyde-fixed tissue samples were immersed in paraffin,
cut into 5 mm-thick slices and stained with (i) hematoxylin and
eosin, (ii) anti-GM2AP, (iii) anti-megalin, (Santa Cruz, Santa Cruz,
CA, USA) and (iv) anti-calbindin (Santa Cruz); followed by
horseradish peroxidase-, fluorescein isothiocyanate- or cyanine
3-conjugated secondary antibodies.
Western blotting
Protein extracts were obtained from renal tissue homogenates
in lysis buffer (25 mmol/l 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid, 150 mmol/l NaCl, 1% Igepal CA-630, 10 mmol/l
MgCl2, 1 mmol/l EDTA, 2% v/v glycerol, 1 mg/ml leupeptin, 1 mg/ml
aprotinin, 5 mmol/l phenylmethylsulfonyl fluoride, 5mM NaF,
1 mmol/l Na3VO4, pH¼ 7.5). A total of 50 mg of tissue lysates,
21 ml of albumin-deprived plasma, or a volume of urine from
each animal corresponding to the same excretion fraction were
subject to polyacrylamide gel electrophoresis, transferred to an
Inmobilon-P membrane (Millipore, Madrid, Spain) and hybridized
with antibodies against KIM-1 (R&D Systems, Minneapolis, MN,
USA and Santa Cruz), neutrophil gelatinase-associated lipocalin
(MBL, Woburn, MA, USA), bone morphogenetic protein 7 (Santa
Cruz Biotechnology), plasminogen activator inhibitor 1 (BD
Biosciences, Madrid, Spain), vimentin (Dako, Glostrup, Denmark),
GM2AP.
Urinary differential proteomic studies
Urine proteins were precipitated and isoelectrically focused
(500–8000 V) through 18-cm long immobilized pH gradient (IPG)
strips, pH 4–7 (GE Healthcare). Then, proteins in IPG strips were
separated by polyacrylamide gel electrophoresis, fixed, and silver
stained. The spots of interest were in-gel digested with porcine
trypsin (Promega, Madrid, Spain). Peptides were extracted and
injected in a liquid chromatography electrospray ionization
quadrupole time-of-flight mass spectrometer QSTAR XL (Applied
Biosystems, Carlsbad, CA, USA) with an 1100 micro high-
performance liquid chromatography (Agilent, Madrid, Spain).
MS/MS spectra were obtained. Mass spectrometry was confirmed
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by matrix-assisted laser desorption/ionization time-of-flight.
Protein identification was performed with the MASCOT software
(http://www.matrixscience.com) against non-redundant protein
sequence databases (Swiss Prot and National Center for Biotechnol-
ogy Information).
Gene expression analysis
reverse transcriptase-PCR amplification of GM2AP and glyceraldehyde
3-phosphate dehydrogenase was performed with the following primers:
for rat GM2AP, 50-ATCAAAAGCCTCACGCTCCA-30 and 50-TATT
TGCCCTTGAGAGAGGC-30; for rat glyceraldehyde 3-phosphate
dehydrogenase, 50-GTGGTCATGAGCCCTTCCA-30 and 50-AACTC
CCTCAAGATTGTCAGCAA-30. PCR conditions were: 1 (95 1C
4 min); 30 (95 1C 1 minþTm 1 min); 1 (72 1C 10 min); where
Tm was 55 1C for GM2AP and 55.9 1C for glyceraldehyde 3-phosphate
dehydrogenase.
Excretion of GM2AP
In a set of experiments, rats were anesthetized and after a single
injection of gentamicin (100 mg/kg), sodium maleate (400 mg/kg)
or saline through the jugular vein, urine fractions were collected
from the bladder during the last 15 min of each subsequent hour,
during 5 h. In another set of experiments, rats were anesthetized and
an extracorporeal circuit for kidney perfusion was set up, as
described58 with some modifications. Briefly, the renal artery, vein,
and ureter of the right kidney were ligated. The renal artery and vein
of the left kidney and the urinary bladder were canulated.
Oxygenated and warm (37 1C) Krebs-dextran (40 g/l of dextran
(molecular weight 64K–76K) in Krebs solution (118.3 mmol/l NaCl,
4.7 mmol/l KCl, 1.8 mmol/l CaCl2, 1.2 mmol/l MgSO4, 1.2 mmol/l
KH2PO4, 25 mmol/l NaHCO3, 0.026 mmol/l EDTA, 11.1 glucose,
pH¼ 7.4)) or Krebs-dextran containing 1.5 mg/ml gentamicin was
perfused through the renal artery at 3 ml/min, and was discarded
through the renal vein. Urine fractions were also collected as before.
All urine samples were kept at 80 1C until assayed by western blot
for the presence of GM2AP.
Human samples
The urine and blood from eight unselected patients treated for at
least 3 days with gentamicin, and the urine from eight sex- and age-
matched untreated donors was obtained from volunteers from the
Hospital Universitario de Salamanca (Spain). Glomerular filtration
rate was estimated by the Modification of Diet in Renal Disease
(MDRD) study or the Cockroft–Gault (C–G) equations.
Statistical analysis
Data are expressed as the average±s.e.m. of the indicated number of
experiments. Statistical analysis was performed by the Scheffe’s test
or the Kruskal–Wallis test, as appropriate. Po0.05 was considered
statistically significant.
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